Syneos Health
Syneos Health, a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself as a key player in the clinical research and commercialisation sectors. Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to navigate the complexities of drug development more effectively. Their innovative approach and commitment to delivering results have positioned them as a trusted partner for pharmaceutical and biotechnology companies. With a strong market presence, Syneos Health has achieved notable milestones, including recognition for its comprehensive service offerings and a focus on patient-centric solutions, making it a preferred choice in the competitive landscape of biopharmaceutical services.
DitchCarbon Score
How does Syneos Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syneos Health's score of 41 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Syneos Health's reported carbon emissions
Syneos Health, headquartered in the United States, has made significant commitments towards reducing its carbon emissions and addressing climate change. Although specific emissions data for the most recent year is not available, the company has set ambitious targets as part of its sustainability initiatives. Syneos Health has committed to achieving net zero carbon emissions by 2040, joining over 300 organisations in signing The Climate Pledge. This long-term goal encompasses all scopes of emissions, reflecting a comprehensive approach to climate action. In the near term, Syneos Health aims to reduce its Scope 1 and 2 emissions by 10% and overall emissions by 5% before 2026. These targets demonstrate the company's proactive stance in mitigating its environmental impact. As of April 2023, Syneos Health is committed to these reduction targets, although it has not yet established a Science-Based Targets initiative (SBTi) target. The company's efforts are part of a broader commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. Overall, Syneos Health's climate commitments highlight its dedication to minimising the impacts of climate change and contributing to a more sustainable future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syneos Health is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
